- Iomervu (Bracco)
- For use as a radiographic contrast agent for various intra-arterial procedures and intravenous procedures.
- Rapiblyk (AOP Orphan Pharmaceuticals)
- For the treatment of supraventricular tachycardia (atrial fibrillation and atrial flutter).
- Imkeldi (Shorla) New Formulation
- Multiple cancer indications for both adults and children – new formulation of imatinib (Gleevec).
- Attruby (BridgeBio)
- For the treatment of adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization.
- Nerivio (Theranica) Expanded Indication
- For acute and/or preventive treatment of migraine with or without aura in patients 8 years of age or older.
- Bimzelx (UCB Pharma)
- For the treatment of adults with moderate to severe hidradenitis suppurativa (HS).
- Ziihera (Jazz)
- For the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.
- Revuforj (Syndax Pharmaceuticals)
- For the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older.
- Danziten (Azurity Pharmaceuticals)
- For adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase and adult patients with chronic phase (CP) and acute phase (AP) resistant or intolerant to prior therapy that included imatinib.
- Kebilidi (PTC Therapeutics)
- For the treatment of AADC deficiency.
- Aucatzyl (Autolus Therapeutics)
- For the treatment of relapsed or refractory adult B-cell acute lymphoblastic leukemia.
- Emrosi (Journey Medical)
- For the treatment of inflammatory lesions of rosacea in adults.
Sign up for alerts and stay informed on the latest published guidelines, FDA decisions, and more!
Copyright © 2024 Guideline Central, All Rights Reserved.